Combination antiangiogenesis therapy with marimastat, captopril and fragmin in patients with advanced cancer
about
CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide.Key feature of the catalytic cycle of TNF-alpha converting enzyme involves communication between distal protein sites and the enzyme catalytic core.Assays for pharmacodynamic analysis of histone deacetylase inhibitors.An integrative somatic mutation analysis to identify pathways linked with survival outcomes across 19 cancer types.Bioavailability of wine-derived phenolic compounds in humans: a review.A state-of-the-art overview of the effect of metabolic conjugation on the biological activity of flavonoids.Anticancer effect and mechanism of polymer micelle-encapsulated quercetin on ovarian cancer.Inhibitory effects of polyphenolic compounds on human arylamine N-acetyltransferase 1 and 2.Cyclooxygenase-2 and inflammation mediators have a crucial role in reflux-related esophageal histological changes and Barrett's esophagus.Synergistic inhibition of angiogenesis by artesunate and captopril in vitro and in vivo.Amelioration of an undesired action of deguelin.Quantitative regioselectivity of glucuronidation of quercetin by recombinant UDP-glucuronosyltransferases 1A9 and 1A3 using enzymatic kinetic parameters.Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy.A novel computational approach for drug repurposing using systems biology.
P2860
Q34437996-22127464-825C-43EB-8CDD-05FD10F47DFFQ35691003-964A7BA1-C713-4A96-95C1-33105D3F36A0Q36546255-1334447F-337B-47C4-A6C3-5D67E7D81B2BQ36967202-0D3619EF-3832-4300-A21D-25B6054452BCQ38021299-62745749-D878-4DFE-AC7E-DBE2AAEE5CE5Q38023192-A9227961-9932-40FA-9DAF-1AC407815EC2Q39264067-E8D59DBB-0D83-48AD-8424-382BBFA36542Q40310408-0200CE85-5FB4-4E78-8BAE-8B838D20C465Q42451322-52526623-6AAA-4317-8427-A3D73ACF91A9Q42923682-C9B5A11A-B2E7-4585-A213-77C219F97988Q42957683-11E95E81-04B2-4C5A-AC91-D4C69041188BQ46879949-BF08A4AD-0943-4B8B-B77E-48D87AAE8DEAQ47863448-6416A097-1386-41EE-BB51-5BE457ED913BQ52657953-F91BF171-4D96-4902-AF9E-9F1B5A89BE09
P2860
Combination antiangiogenesis therapy with marimastat, captopril and fragmin in patients with advanced cancer
description
2004 nî lūn-bûn
@nan
2004 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Combination antiangiogenesis t ...... patients with advanced cancer
@ast
Combination antiangiogenesis t ...... patients with advanced cancer
@en
Combination antiangiogenesis t ...... patients with advanced cancer
@nl
type
label
Combination antiangiogenesis t ...... patients with advanced cancer
@ast
Combination antiangiogenesis t ...... patients with advanced cancer
@en
Combination antiangiogenesis t ...... patients with advanced cancer
@nl
prefLabel
Combination antiangiogenesis t ...... patients with advanced cancer
@ast
Combination antiangiogenesis t ...... patients with advanced cancer
@en
Combination antiangiogenesis t ...... patients with advanced cancer
@nl
P2093
P2860
P50
P356
P1476
Combination antiangiogenesis t ...... patients with advanced cancer
@en
P2093
A J Kakkar
D C Talbot
K Christodoulos
N Gompertz
T S Ganesan
P2860
P2888
P356
10.1038/SJ.BJC.6601897
P407
P577
2004-07-01T00:00:00Z
P5875
P6179
1041308623